Terminated PHASE1 INTERVENTIONAL 1-arm NCT04178460

A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment

A Multicenter, Open-label, Single-arm, Phase Ib Dose Escalation and Multi-cohort Expansion Clinical Study to Assess the Safety and Antitumor Activity of Niraparib in Combination With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment

Sponsor: Zai Lab (Shanghai) Co., Ltd.

Conditions Biliary Tract Carcinoma Endometrial Carcinoma Gastric Cancer Triple Negative Breast Cancer

Interventions Niraparib combined with MGD013

Updated 14 times since 2019 Last updated: May 25, 2022 Started: Feb 3, 2020 Primary completion: Mar 2, 2022 Completion: Mar 2, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This termination decision is a business decision and is not due to any safety concerns.

This PHASE1 trial investigates Biliary Tract Carcinoma and Endometrial Carcinoma and is currently terminated or withdrawn. Zai Lab (Shanghai) Co., Ltd. leads this study, which shows 14 recorded versions since 2020 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

14 versions recorded

Jan 2026 — Present [monthly]

Terminated PHASE1
Sep 2025 — Present [monthly]

Terminated PHASE1
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE1
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1
Jul 2022 — Jul 2024 [monthly]

Terminated PHASE1

Status: Recruiting → Terminated

▶ Show 9 earlier versions

Mar 2022 — Jul 2022 [monthly]

Recruiting PHASE1
Oct 2021 — Mar 2022 [monthly]

Recruiting PHASE1
May 2021 — Oct 2021 [monthly]

Recruiting PHASE1
Jan 2021 — May 2021 [monthly]

Recruiting PHASE1
Sep 2020 — Jan 2021 [monthly]

Recruiting PHASE1
Jul 2020 — Sep 2020 [monthly]

Recruiting PHASE1
Apr 2020 — Jul 2020 [monthly]

Recruiting PHASE1
Mar 2020 — Apr 2020 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Dec 2019 — Mar 2020 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Zai Lab (Shanghai) Co., Ltd.

Data source: Zai Lab (Hong Kong), Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Beijing, China , Chengdu, China , Guangzhou, China , Hangzhou, China , Ha’erbin, China , Hong Kong, China , Shanghai, China , Shenyang, China , Taizhou, China , Tianjin, China and 4 more locations